Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Danazol for benign breast disease

C Nezhat, R H Asch, R B Greenblatt

    American Journal of Obstetrics and Gynecology
    |July 1, 1980
    PubMed
    Summary

    Danazol effectively treats fibrocystic breast disease, with two-thirds of women experiencing complete nodularity elimination. This hormonal agent demonstrated minimal side effects, making it a valuable option for managing breast conditions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A proof of concept that experience-based management of endometriosis can complement evidence-based guidelines.

    Facts, views & vision in ObGyn·2023
    Same author

    Predictive factors and treatment of recurrence of endometriosis.

    Minerva ginecologica·2013
    Same author

    Laparoscopic surgery for gynecologic cancer.

    Surgical technology international·2011
    Same author

    Endometriosis of the intestine and genitourinary tract.

    Surgical technology international·2011
    Same author

    Menopausal arthritis.

    The Medical clinics of North America·2010
    Same author

    Treatment of granuloma inguinale with diramin; a new antimonial.

    The Journal of venereal disease information·2010

    Area of Science:

    • Endocrinology
    • Gynecology
    • Oncology

    Background:

    • Fibrocystic breast disease is a common benign condition affecting women.
    • Hormonal therapies are often explored for managing breast pain and nodularity.

    Purpose of the Study:

    • To evaluate the efficacy and safety of danazol in treating women with benign breast disease.
    • To determine optimal dosage and long-term outcomes of danazol therapy.

    Main Methods:

    • A study involving three groups of women (total 130) with benign breast disease.
    • Treatment with danazol at doses of 100 mg, 200 mg, or 400 mg daily for 3-6 months.
    • Patients were monitored for up to 48 months post-therapy with regular follow-ups.

    Main Results:

    • Complete resolution of breast nodularity was observed in approximately two-thirds of patients.
    • Partial improvement was noted in the remaining patients, with only three experiencing no significant benefit.
    • Reported side effects associated with danazol treatment were minimal and generally trivial.

    Conclusions:

    • Danazol is an effective hormonal agent for managing fibrocystic breast disease.
    • The treatment shows a high rate of efficacy with a favorable safety profile.
    • Long-term follow-up suggests sustained benefits in managing benign breast conditions.

    Related Experiment Videos